North Star Investment Management Corp. Sells 27 Shares of Eli Lilly and Company $LLY

North Star Investment Management Corp. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,161 shares of the company’s stock after selling 27 shares during the quarter. North Star Investment Management Corp.’s holdings in Eli Lilly and Company were worth $6,362,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Missouri Trust & Investment Co lifted its position in shares of Eli Lilly and Company by 5.5% during the second quarter. Missouri Trust & Investment Co now owns 1,115 shares of the company’s stock worth $869,000 after purchasing an additional 58 shares during the last quarter. Regatta Capital Group LLC lifted its position in shares of Eli Lilly and Company by 5.1% during the second quarter. Regatta Capital Group LLC now owns 966 shares of the company’s stock worth $753,000 after purchasing an additional 47 shares during the last quarter. Signal Tree Financial Partners LLC purchased a new position in shares of Eli Lilly and Company during the second quarter valued at $203,000. Total Wealth Planning LLC purchased a new position in shares of Eli Lilly and Company during the second quarter valued at $24,168,000. Finally, Retireful LLC increased its stake in shares of Eli Lilly and Company by 13.8% during the second quarter. Retireful LLC now owns 510 shares of the company’s stock valued at $398,000 after buying an additional 62 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $742.51 on Thursday. The business’s 50-day moving average is $736.05 and its two-hundred day moving average is $768.68. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $939.30. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market capitalization of $702.75 billion, a PE ratio of 48.53, a price-to-earnings-growth ratio of 1.04 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research reports. Berenberg Bank restated a “hold” rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Leerink Partners restated a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Finally, UBS Group cut their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $939.61.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.